AGTR1: IHC Expression in Cancer and Radioligand Target Profile
AGTR1, angiotensin II receptor type 1, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, AGTR1 staining is highest in lung cancer (8% of samples positive) and endometrial cancer (8% of samples positive). Evidence on whether AGTR1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is AGTR1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze AGTR1 freeIs AGTR1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Low IHC staining in lung cancer, 8% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
AGTR1 IHC staining by cancer type
Protein expression of AGTR1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lung Cancer | 0.03 | Low | 8% |
| Endometrial Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, glioma, liver cancer.
Is AGTR1 internalized?
Uncertain. The abstract discusses familial hypercholesterolemia and LDL receptor internalization but does not provide specific information about AGTR1 internalization or endocytosis.
Sources: PMID 41492187 · PMID 36281440 · PMID 35612431 · PMID 25380825 · PMID 17456551. AI-extracted from abstracts, so verify before citing.
AGTR1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for AGTR1 yet. Search ClinicalTrials.gov for AGTR1 trials.
AGTR1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See AGTR1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
AGTR1 gene essentiality (DepMap)
CRISPR knockout effect across 1239 cancer cell lines: -0.07 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lung cancer radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · EPCAM · CEA (CEACAM5) · STEAP2 · B7-H3 (CD276) · Mesothelin (MSLN)
See all radioligand therapy targets in lung cancer.
See how AGTR1 ranks against 15,000 targets for your indication.
Analyze AGTR1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.